HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Killough, J. H. Articles by Magill, G. B. Search for Related Content PubMed PubMed Citation Articles by Killough, J. H. Articles by Magill, G. B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Antibiotics Hazardous Substances DB OXYTETRACYCLINE

A Comparative Study of Fumagillin and Oxytetracycline in Amebiasis

Of 115 patients treated for amebiasis, 67 were given fumagillin and 48, oxytetracycline. Patients with dysentery are considered separately because of differences in severity of illness, the development of extra-intestinal lesions, slower response and occurrence of relapses while still hospitalized.

Among 13 patients with dysentery receiving fumagillin, two developed hepatic abscess while under treatment. One of the patients with abscess died although receiving concomitant chloroquine. The other recovered after change of therapy to oxytetracycline and chloroquine. Two had recurrence of amebae while still hospitalized.

Sixteen patients with dysentery received oxytetracycline. Two developed hepatic abscess on treatment and one presumably had an unrecognized abscess on admission. The latter died on the sixth day of oxytetracycline therapy. Each of the remaining two received concomitant chloroquine. One recovered rapidly; the other died.

Of 86 patients with nondysenteric amebiasis, 54 were treated with fumagillin and 32 with oxytetracycline. On adequate dosage, there were no recurrences in either group during a minimal post-treatment period of 4 weeks in the hospital. Excluding the side effects of fumagillin, there were no significant differences in parasitologic or clinical response.

The environmental conditions to which these patients were exposed after release from the hospital are such as to render impossible an accurate evaluation of cure rates on the basis of prolonged follow-up.

¹ Department of Clinical Investigation, U. S. Naval Medical Research Unit No. 3, Cairo, Egypt.

² This study has made possible through the cooperation of the Egyptian Ministry of Health.

³ The opinions or assertions contained herein are the private ones of the writers and are not to be construed as official or reflecting the views of the Navy Department or the naval service at large.